Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
McKinsey
Colorcon
Boehringer Ingelheim
McKesson

Last Updated: October 6, 2022

Details for Patent: 9,662,340


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 9,662,340 protect, and when does it expire?

Patent 9,662,340 protects VOGELXO and is included in one NDA.

This patent has eight patent family members in eight countries.

Summary for Patent: 9,662,340
Title:Testosterone gel compositions and related methods
Abstract: Described are gel compositions containing active pharmaceutical ingredient such as testosterone, solvent, and thickener, the gel compositions being useful for transdermal administration of the active ingredient to a patient, and related methods. Certain embodiments of the gel composition specifically exclude Hsieh enhancer.
Inventor(s): Pimplaskar; Harish K. (Charlotte, NC)
Assignee: UPSHER-SMITH LABORATORIES, INC. (Maple Grove, MN)
Application Number:15/081,402
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,662,340

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Upsher Smith Labs VOGELXO testosterone GEL, METERED;TRANSDERMAL 204399-003 Jun 4, 2014 BX RX No No See Plans and Pricing See Plans and Pricing Y METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE See Plans and Pricing
Upsher Smith Labs VOGELXO testosterone GEL;TRANSDERMAL 204399-002 Jun 4, 2014 AB2 RX No No See Plans and Pricing See Plans and Pricing Y METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,662,340

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014362275 See Plans and Pricing
Canada 2857286 See Plans and Pricing
European Patent Office 3079703 See Plans and Pricing
Hong Kong 1223852 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Dow
Moodys
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.